In Currax's new campaign for weight loss med Contrave, the focus is on emotional eating — reaching for cookies for comfort, for instance.

August 31, 2022 02:40 PM EDTUpdated 07:05 PM

Marketing

Currax doubles down on ‘pioneer’ weight-loss med Contrave in newly energized obesity drug market

Beth Snyder Bulik

Senior Editor

Obesity is in the spotlight thanks to a raft of new and pending therapies in the pipeline. However, Currax Pharmaceuticals’ Contrave, the old guard of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Currax doubles down on ‘pioneer’ weight-loss med Contrave in newly energized obesity drug market

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Cur­rax dou­bles down on ‘pi­o­neer’ weight-loss med Con­trave in new­ly en­er­gized obe­si­ty drug mar­ket

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

more like this

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

Currax doubles down on ‘pioneer’ weight-loss med Contrave in newly energized obesity drug market

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA